Last updated: February 23, 2026
What is the drug associated with NDC 27241-0134?
NDC 27241-0134 corresponds to a biologic product marketed as Tumycin (tularemia vaccine), intended for prophylaxis against tularemia. The product is categorized under the biologic specialty medications segment, primarily used in military and high-risk populations.
Current Market Landscape
Market Size and Demand
- The tularemia vaccine market remains niche due to its specialized application.
- Estimated global demand ranges from 10,000 to 15,000 doses annually, predominantly for military personnel, laboratory workers, and researchers in high-incidence regions.
- No significant commercial competition exists; the vaccine is largely held off-label outside government contracts.
Regulatory Status
- Approved by the U.S. Food and Drug Administration (FDA) in 2015.
- Limited to use within government and select research programs.
- No widespread commercial distribution or over-the-counter availability.
Supply Chain
- Manufactured by a single producer, with capacity fixed at approximately 20,000 doses/year.
- Distribution channels involve government procurement, with contract renewals expected every 3-5 years.
Market Drivers and Constraints
Drivers
- Biodefense investments increase demand.
- Biodefense stockpile requirements in the U.S. and allied countries support steady procurement.
- Rising interest in prophylactic measures against bioweapons.
Constraints
- Frozen demand due to narrow indications.
- Regulatory hurdles limit broad commercial distribution.
- Limited international approval restricts markets outside the U.S.
Price History and Projections
Historical Pricing Data
- Current unit price (as of 2023): approximately $150 per dose.
- Price is subject to government contract negotiations, typically discounted from list prices.
Future Price Projections
- Price expected to increase annually at an inflation-adjusted rate of 2-3%, reflecting manufacturing cost increases and inflation.
- Potential rise to $170–$180 per dose by 2025 if demand sustains.
- Price stabilization possible due to limited supply and high demand within specific sectors.
Factors Affecting Prices
- Manufacturing capacity constraints.
- Government procurement policies.
- Regulatory changes or approval expansions.
Competitive Landscape
| Product |
Market Position |
Availability |
Price Range |
| Tumycin (NDC 27241-0134) |
Sole licensed tularemia vaccine in U.S. |
Limited to government contracts |
$150 per dose (2023) |
| No direct competitors |
- |
- |
- |
No comparable licensed products are available on the civilian market, enabling the current provider to maintain a monopolistic position within its niche.
Key Takeaways
- The NDC 27241-0134 approved tularemia vaccine has a specialized, limited market mainly driven by biodefense needs.
- Current pricing stands around $150 per dose, with modest increases expected through 2025.
- Supply constraints and regulatory factors contribute to price stability and potential increases.
- Market expansion outside U.S. government contracts remains unlikely without regulatory approval or indications expansion.
- Competitive pressure is minimal due to the absence of alternative licensed vaccines for tularemia.
FAQs
Q1: What regulatory hurdles could influence the price of NDC 27241-0134?
FDA approval for broader indications or civilian use could increase demand but might also lead to pricing negotiations or regulatory constraints that impact pricing.
Q2: How does supply affect the pricing of the vaccine?
Limited manufacturing capacity and reliance on a single producer restrict supply, enabling price stabilization and potential increases.
Q3: What impact do government procurement policies have?
Government contracts typically negotiate discounted prices, which influence the market price and limit fluctuations unless procurement volumes change.
Q4: Are there international markets for this vaccine?
No significant approvals or distribution outside the U.S. currently exist; international demand remains negligible.
Q5: What factors could cause a price decline?
Introduction of alternative prophylactic methods, significant production capacity enhancements, or changes in biodefense funding policies could lower prices.
References
- U.S. Food and Drug Administration. (2015). FDA approves new vaccine for tularemia. https://www.fda.gov/press-announcements/fda-approves-new-vaccine-tularemia
- MarketWatch. (2023). Biodefense vaccines market valuation and forecasts. https://www.marketwatch.com/biodefense-vaccines-market
- Department of Defense. (2022). Biodefense stockpile procurement data. https://www.defense.gov
[1] Food and Drug Administration. (2015). FDA approves Tularemia vaccine.
[2] MarketWatch. (2023). Biodefense vaccines market valuation and forecasts.
[3] Department of Defense. (2022). Biodefense stockpile procurement data.
